October 14, 2020

Oncopeptides signs € 40 million loan agreement with the EIB

STOCKHOLM — October 14, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Inves...
Read more
October 13, 2020

Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer

The pre-defined disease control efficacy threshold in part 1 in the colorectal cancer cohort has been met The colorectal expansion cohort has been opened for recruitment o...
Read more
October 12, 2020

Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)

Financing to advance mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, and potential best-in-class therapy for AML patients DUBLIN, Ireland –  12th Oc...
Read more
October 12, 2020

With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA

TOCKHOLM — October 12, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its...
Read more
October 12, 2020

Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors

Oslo, 12 October 2020: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-tr...
Read more
October 9, 2020

Spruce Biosciences Announces Pricing of Upsized Initial Public Offering

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine di...
Read more
October 8, 2020

Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models

Oslo, Norway, 8 October 2020 Nordic Nanovector ASA (OSE: NANO) announces that its preclinical study investigating the ability of Betalutin® (177Lu-lilotomab satetraxe...
Read more
October 7, 2020

Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer...
Read more
October 1, 2020

Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma

STOCKHOLM — October 1, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. pa...
Read more
October 1, 2020

Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial

Gothenburg, October 1, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces ...
Read more